GlassScriptPhysician profile
Veronica Viramontes
NPI 1902833460
$930.93
in general payments reported to CMS, 2019-2025
9 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $20.01 · 2023: $127 · 2024: $287 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $780 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.71 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $330.24 | 2023-2025 | Filspari |
| Fresenius USA Marketing, INC. | $196.12 | 2021-2024 | Velphoro |
| Ardelyx, INC. | $112.34 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $82.02 | 2023-2024 | Auryxia, Vafseo |
| Opko Pharmaceuticals, LLC | $63.18 | 2023-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $60.00 | 2024 | |
| Horizon Therapeutics Plc | $35.36 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $27.51 | 2025 | Jynarque |
| Vifor Pharma, INC. | $24.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Viramontes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.